Canada Pension Plan Investment Board’s Contineum Therapeutics CTNM Stock Holding History

Canada Pension Plan Investment Board’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$269K	Buy	+20,600	New	+$276K	﹤0.01%	1465

Other funds holding CTNM

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Canada Pension Plan Investment Board's CTNM Position: Q1 2026 in Review

Canada Pension Plan Investment Board opened a new position in Contineum Therapeutics (CTNM) in Q1 2026: 20,600 shares worth $269K. The stake represents ﹤0.01% of the portfolio and ranks #1465 among its holdings.

90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

Canada Pension Plan Investment Board held 20,600 shares of Contineum Therapeutics worth $269K as of Q1 2026.
Contineum Therapeutics was a new Canada Pension Plan Investment Board position in Q1 2026.
Contineum Therapeutics made up ﹤0.01% of Canada Pension Plan Investment Board's portfolio in Q1 2026, its #1465 holding.
90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Canada Pension Plan Investment Board's 13F filing for Q1 2026, filed 15 May 2026.